Search Main Menu Main Content
  • Change contrast :
Haute Autorité de Santé
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Active substance : clopidogrel
  • Active substance : bivalirudine
Filter
Topic
  • Economics and public health (1)
  • Plus ...
    • Health economics (1)
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Protheses and implants (1)
  • Diseases and conditions (1)
  • Plus ...
    • Heart diseases (1)
    • Plus ...
      • Myocardial ischemia (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Health technology assessment (1)
Manufacturer
  • industriels (1)
Language
  • Français (1)
Active substance
  • acide salicylique (1)
  • aspirine (1)
  • bivalirudine (1)
  • chrome (1)
  • clopidogrel (1)
  • cobalt (1)
  • ivabradine (1)
  • paclitaxel (1)
  • prasugrel (1)
  • sirolimus (1)

Drugs, devices and medical acts - 1 result

  • Assessment of drug-eluting stents

    Health technology assessment - Posted on 19/2/2010
    Download document
    Add to my selection
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
3PsFUC3aXW4dGseB